Condition: Lung Cancer · Immune Checkpoint Inhibitor · Radiotherapy · Sponsor: Xinqiao Hospital of Chongqing
Investigators intend to combine low-dose hypersensitivity with high-dose immunopotentiation effect, and use super-hyperfractionation pulse radiotherapy, which is expected to achieve the effect of in situ vaccine that can enhance tumor killing, protect normal tissues, reduce immune cell damage and enhance tumor immunogenicity at the same time, and play a stronger immunopotentiation effect in combined immunotherapy. Thereby inducing a stronger abscopal effect of radiotherapy.
This description comes directly from the study's public registry record.
Jianguo Sun, doctor · +862368774490 · sunjianguo@tmmu.edu.cn
Lin-Peng Zheng · +862368774395 · zlpxiangya@163.com
Always discuss trial participation with your own doctor first.
| the second affiliated hospital of Army medical university | Chongqing, Chongqing Municipality, China | Recruiting |
| Jianguo Sun | Chongqing, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05754203